No Data
10-Q: Quarterly report
Scilex Provides Information To Stockholders Regarding Manipulative And Naked Short Selling Of Its Common Stock
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for t
Scilex Holding Is Maintained at Buy by HC Wainwright & Co.
Scilex Holding Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : The Scilex Holding (SCLX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $8.00.
HC Wainwright & Co. : The Scilex Holding (SCLX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $8.00.
HC Wainwright & Co. Maintains Buy on Scilex Holding, Lowers Price Target to $8
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Scilex Holding (NASDAQ:SCLX) with a Buy and lowers the price target from $12 to $8.
Scilex Holding Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 831.15% HC Wainwright & Co. $12 → $8 Maintains Buy 12/04/2023 1296.73% HC Wainwright & Co. → $1